BioSpace News Archive

New Orleans-based Revolo Biotherapeutics, formerly known as Immune Regulation, rebranded to reflect its revolutionary scientific approach to dramatically alter the autoimmune and allergic disease treatment landscape.

Findings from a second interim analysis of a first-in-human Phase I/II clinical trial of Translate Bio’s CF mRNA candidate, MRT5005, show the drug did not significantly improve lung function in patients with CF.

Multiple pharmaceutical companies struck large licensing deals with one another this week. Here’s a look.

The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.

Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with interim data from lead oncology and infectious disease candidates Follow-on offering strengthened cash basis with $143 million available at year-end to support progression of Human Papillomavirus 16-positive (HPV16+) cancer and Cytomegalovirus (CMV) programs and pipeline expansion HOOKIPA on track to report additional clinical data on efficacy and T cell response in 2021 for HB-201 and HB-202

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™

Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma

Boston Pharmaceuticals announced today a pioneering three-year out-license and option agreement with GlaxoSmithKline PLC (LSE/NYSE: GSK). Boston Pharmaceuticals will become a preferred GSK partner for select pre-phase 2 programs. This new agreement builds on the relationship established in 2018 with Boston Pharmaceutic

- Year-end 2020 cash, cash equivalents and marketable securities of $326.5 million, with projected runway into the second half of 2023 - Four antibody-drug conjugate programs are now in the clinic that were discovered through Sutro’s proprietary and integrated cell-free protein synthesis platform

Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.